CD274 and hepatocellular carcinoma: Recently, the combination tremelimumab (a cytotoxic T lymphocyte-associated antigen-4 blocking antibody) plus durvalumab (anti PD-L1 monoclonal antibody) has been approved in the USA for the treatment of adult patients with unresectable HCC [42].